Selinexor
- Generic Name
- Selinexor
- Brand Names
- Xpovio 100 Mg Once Weekly Carton, Nexpovio
- Drug Type
- Small Molecule
- Chemical Formula
- C17H11F6N7O
- CAS Number
- 1393477-72-9
- Unique Ingredient Identifier
- 31TZ62FO8F
- Background
Selinexor is a first-in-class selective inhibitor of nuclear transport (SINE) compound. Selinexor, in combination with bortezomib and dexamethasone, is currently approved for the treatment of multiple myeloma, a type of cancer formed from antibody-producing plasma cells. This condition is typically treated with high dose bortezomib and dexamethasone chemothe...
- Indication
Selinexor is indicated in combination with bortezomib and dexamethasone for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. Selinexor is also indicated in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma in adult patients who have received at least four prior therapi...
- Associated Conditions
- Multiple Myeloma (MM), Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Relapsed Diffuse large B-cell lymphoma NOS
- Associated Therapies
- -
Selinexor in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2017-03-06
- Last Posted Date
- 2020-05-22
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 37
- Registration Number
- NCT03071276
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
🇺🇸Phoenix Children's Hospital, Phoenix, Arizona, United States
Study of Selinexor and Doxorubicin in Advanced Soft Tissue Sarcomas
- First Posted Date
- 2017-02-03
- Last Posted Date
- 2021-12-09
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 25
- Registration Number
- NCT03042819
- Locations
- 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Selinexor With Combination With Induction/Consolidation Therapy in Acute Myeloid Leukemia Patients
- Conditions
- Interventions
- First Posted Date
- 2016-07-18
- Last Posted Date
- 2024-04-30
- Lead Sponsor
- Wake Forest University Health Sciences
- Target Recruit Count
- 100
- Registration Number
- NCT02835222
- Locations
- 🇺🇸
Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States
A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With Myeloma
- Conditions
- Interventions
- First Posted Date
- 2016-07-13
- Last Posted Date
- 2020-11-24
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 18
- Registration Number
- NCT02831686
- Locations
- 🇺🇸
Memoral Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Nassau, Uniondale, New York, United States
Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2016-05-23
- Last Posted Date
- 2022-11-04
- Target Recruit Count
- 22
- Registration Number
- NCT02780609
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDP
- Conditions
- Interventions
- First Posted Date
- 2016-04-18
- Last Posted Date
- 2021-12-07
- Lead Sponsor
- The Lymphoma Academic Research Organisation
- Target Recruit Count
- 39
- Registration Number
- NCT02741388
- Locations
- 🇫🇷
CHU Dijon, Dijon, France
🇫🇷CHRU de Lille - Hôpital Claude Huriez, Lille, France
🇧🇪Institut Jules Bordet, Bruxelles, Belgium
Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2015-12-11
- Last Posted Date
- 2023-01-26
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Registration Number
- NCT02628704
- Locations
- 🇺🇸
James R. Berenson MD, Inc, West Hollywood, California, United States
🇺🇸Waverly Hematology, Cary, North Carolina, United States
Selinexor in Advanced Liposarcoma
- First Posted Date
- 2015-11-17
- Last Posted Date
- 2023-01-23
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 342
- Registration Number
- NCT02606461
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Sarcoma Oncology Center, Santa Monica, California, United States
🇺🇸University of Pittsburgh Medical Center (UPMC), Pittsburgh, Pennsylvania, United States
Selinexor With Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2015-10-09
- Last Posted Date
- 2020-04-08
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 25
- Registration Number
- NCT02573363
- Locations
- 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
Selinexor and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Lung Cancer
- First Posted Date
- 2015-09-01
- Last Posted Date
- 2015-10-30
- Lead Sponsor
- Erin Bertino
- Registration Number
- NCT02536495
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.